Key Takeaways
- • OliX Pharmaceuticals (KOSDAQ: 226950) raised approximately KRW 110 billion through a third-party allotment of newly issued common shares to strategic investors, per its Business Wire announcement.
- • The round was jointly made by BOLD, L'Oréal's corporate venture capital arm, and Weiss Asset Management LP, a U.S. asset manager.
- • Weiss is a repeat backer, having invested in OliX in August 2025 and participating again in this round.
- • Proceeds will fund ongoing siRNA projects in skin and hair indications and deepen the strategic partnership with L'Oréal.
- • The deal pairs a strategic beauty-industry partner with a global financial investor, which management cites as evidence of market confidence in its RNAi platform.
Summary
OliX Pharmaceuticals, Inc., a Seoul-based developer of RNA interference (RNAi) therapeutics listed on KOSDAQ under ticker 226950, announced that it has raised approximately KRW 110 billion through a third-party allotment of newly issued common shares to strategic investors, according to a Business Wire release dated June 4, 2026.
The investment was made jointly by BOLD, the venture investment arm of L'Oréal that backs beauty, biotech and technology companies with disruptive potential, and Weiss Asset Management LP, a U.S. asset management firm. The company describes Weiss as a key global investor that participated in this round following its earlier investment in August 2025.
OliX said it will use the proceeds to advance its ongoing siRNA-based programs across several therapeutic areas, including skin- and hair-related projects. The company also expects the funding to strengthen its strategic partnership with L'Oréal and to reinforce its research foundation and accelerate development timelines.
Guive Balooch, Global Managing Director of Open Innovation and Augmented Beauty at L'Oréal, said the equity investment would strengthen the scientific partnership and combine OliX's siRNA platform with L'Oréal's expertise in biology, technology and formulation. CEO Dong Ki Lee said the company was delighted to secure the funding and that the participation of a global strategic partner and a major investor reflects market confidence in the company's technological competitiveness and growth potential.
OliX develops therapeutics based on its proprietary OASIS (OliX Advanced Small Interfering RNA System) platform, which is designed to enhance gene-silencing efficiency and enable tissue-specific delivery. Its locally administered programs target hair loss, age-related macular degeneration and hypertrophic scars, while hepatocyte-specific delivery technology supports liver pipelines in metabolic dysfunction-associated steatohepatitis (MASH), obesity and cardiometabolic disorders. Under its "OliX 2.0 Roadmap," the company is also building delivery platforms for the central nervous system and adipose tissue.
The investment was made jointly by BOLD, the venture investment arm of L'Oréal that backs beauty, biotech and technology companies with disruptive potential, and Weiss Asset Management LP, a U.S. asset management firm. The company describes Weiss as a key global investor that participated in this round following its earlier investment in August 2025.
OliX said it will use the proceeds to advance its ongoing siRNA-based programs across several therapeutic areas, including skin- and hair-related projects. The company also expects the funding to strengthen its strategic partnership with L'Oréal and to reinforce its research foundation and accelerate development timelines.
Guive Balooch, Global Managing Director of Open Innovation and Augmented Beauty at L'Oréal, said the equity investment would strengthen the scientific partnership and combine OliX's siRNA platform with L'Oréal's expertise in biology, technology and formulation. CEO Dong Ki Lee said the company was delighted to secure the funding and that the participation of a global strategic partner and a major investor reflects market confidence in the company's technological competitiveness and growth potential.
OliX develops therapeutics based on its proprietary OASIS (OliX Advanced Small Interfering RNA System) platform, which is designed to enhance gene-silencing efficiency and enable tissue-specific delivery. Its locally administered programs target hair loss, age-related macular degeneration and hypertrophic scars, while hepatocyte-specific delivery technology supports liver pipelines in metabolic dysfunction-associated steatohepatitis (MASH), obesity and cardiometabolic disorders. Under its "OliX 2.0 Roadmap," the company is also building delivery platforms for the central nervous system and adipose tissue.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.